Cancer Circulatory System Digestive System Ear, Nose and Throat Eye Diseases Genetic Diseases Haematological Disorders HIV/AIDS Tuberculosis Malaria Ebola Injury, Occupational Diseases, Poisoning Mental and Behavioural Disorders Musculoskeletal Diseases Neonatal Diseases Nervous System Diseases Nutritional, Metabolic, Endocrine Oral Health Pregnancy and Childbirth Respiratory Skin and Connective Tissue Diseases Urological and Genital Diseases Fertility-male Fertility-femal
Conditions
Interventions
Continuity Genome Restorer
Sponsors
SCVX Validator Economy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants must meet all of the following: Age: 13–80 years old. Residence: Must reside in one of the participating African countries during the trial period. Diagnosis: Clinically diagnosed with at least one of the following conditions: Blood disorders (e.g., sickle cell disease, anemia, rare bone marrow failure). Diabetes (Type 1 or Type 2). Chronic kidney disease or history of kidney failure. Chronic wound infections (non-healing wounds, risk of amputation). Bone infections or degeneration (osteomyelitis, fracture non-healing, arthritis-related degeneration). HIV/AIDS with ongoing immune compromise despite treatment. Organ failure (early-to-moderate stage heart, liver, or lung dysfunction). Neurodegenerative diseases (early-stage Parkinson’s, Alzheimer’s, multiple sclerosis). Autoimmune conditions (e.g., lupus, rheumatoid arthritis). Psychosis or severe psychiatric disorders not responding to conventional therapy. Disease Stage: Must have conditions considered non-responsive or poorly responsive to conventional treatments, or where invasive/life-threatening interventions (amputation, transplant, lifelong drug dependency) are being considered. Consent/Assent: Adults (=18 years): Able and willing to provide written informed consent. Adolescents (13–17 years): Able to provide assent, with parental/guardian consent required. Commitment: Willing to attend all CGR sessions and follow-up visits for the full 24-month trial duration.
Exclusion criteria
Exclusion criteria: Participants will not be eligible if they meet any of the following: Age: Younger than 13 years or older than 80 years. Pregnancy and Breastfeeding: Pregnant or breastfeeding women. Pregnant adolescents (13–17 years) are excluded due to unknown resonance effects on fetal/infant development. Guardian Refusal: Adolescents (13–17 years) whose parent/guardian does not provide written consent. Active Cancer: Currently undergoing chemotherapy, radiotherapy, or other aggressive cancer treatments. Severe Psychiatric Illness: Individuals with uncontrolled psychiatric or cognitive conditions (e.g., schizophrenia with acute crisis, severe dementia) that impair ability to consent/assent or comply with study requirements. Substance Abuse: Active alcohol or substance abuse likely to interfere with adherence. Medical Instability: Patients with advanced, unstable, or end-stage organ failure (e.g., requiring mechanical ventilation, dialysis dependence without residual function, end-stage liver failure). Concurrent Experimental Therapy: Participation in another interventional clinical trial within the last 6 months. Non-Adherence Risk: Inability or unwillingness to attend the 3 core CGR sessions and monthly follow-ups for 24 months. Contraindication to Resonance Monitoring: Presence of implanted electronic medical devices (e.g., certain pacemakers, defibrillators) that could interfere with resonance mapping.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcomes ? Restoration of genomic continuity resonance as measured by continuity resonance mapping (baseline vs post-intervention). Clinical disease reversal indicators, including: Blood regeneration (hemoglobin, white cell, platelet counts). Kidney/liver function markers (creatinine, ALT/AST). Wound closure rates and bone healing (radiological and clinical). Glucose regulation (HbA1c for diabetes). | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life improvements (mobility, pain reduction, energy levels, sleep). Prevention of invasive interventions (avoidance of amputations, transplants, or lifelong drug escalation). Telomere length restoration and markers of aging reversal. Immune system regeneration in HIV/AIDS and chronic infections. Patient-reported outcomes (emotional well-being, ability to work, daily functioning). Long-term durability of CGR effects (12–24 months follow-up). | — |
Countries
Botswana, Egypt, Ghana, Kenya, Lesotho, Namibia, Nigeria, Rwanda, South Africa, Swaziland, Uganda
Contacts
Public ContactSsemakula;Ssemakula Luyima;Luyima
Principal Investigator;Principal Investigator
Outcome results
None listed